Further Data Analysis of Bionomics' Phase 2 Post Traumatic Stress Disorder Trial Shows the Potential for Significant Patient Benefit When Drug Exposure Is Adequate
ADELAIDE, Australia--(BUSINESS WIRE)--Feb 18, 2019--Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, announces that an additional data…
